1. Systemic administration of low-dose naltrexone increases bone mass due to blockade of opioid growth factor receptor signaling in mice osteoblasts
    Kenjiro Tanaka et al, 2019, Life Sciences CrossRef
  2. The Safety and Efficacy of Low-Dose Naltrexone in the Management of Chronic Pain and Inflammation in Multiple Sclerosis, Fibromyalgia, Crohn's Disease, and Other Chronic Pain Disorders
    Denise K. Patten et al, 2018, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy CrossRef
  3. Preclinical and clinical studies into the bioactivity of low-dose naltrexone (LDN) for oncotherapy
    Na Qu et al, 2021, International Immunopharmacology CrossRef
  4. Endogenous opiates and behavior: 2017
    Richard J. Bodnar, 2020, Peptides CrossRef
  5. Bioresponsive nanostructured systems for sustained naltrexone release and treatment of alcohol use disorder: Development and biological evaluation
    Rogério A. Santos et al, 2020, International Journal of Pharmaceutics CrossRef
  6. Immunometabolic Modulatory Role of Naltrexone in BV-2 Microglia Cells
    Natalia Kučić et al, 2021, International Journal of Molecular Sciences CrossRef
  7. Functional modulation on macrophage by low dose naltrexone (LDN)
    Zhe Yi et al, 2016, International Immunopharmacology CrossRef
  8. Naltrexone’s Impact on Cancer Progression and Mortality: A Systematic Review of Studies in Humans, Animal Models, and Cell Cultures
    Karina Liubchenko et al, 2021, Advances in Therapy CrossRef
  9. Successive treatment with naltrexone induces epithelial–mesenchymal transition and facilitates the malignant biological behaviors of bladder cancer cells
    Xiaoqiang Wang et al, 2021, Acta Biochimica et Biophysica Sinica CrossRef
  10. Is immunity in cancer the key to improving clinical outcome?: Report on the International Symposium on Immunotherapy, The Royal Society, London, UK, 12–13 May 2017
    Peter L. Stern, 2017, Therapeutic Advances in Vaccines CrossRef
  11. Low-dose naltrexone (LDN): A promising treatment in immune-related diseases and cancer therapy
    Zijian Li et al, 2018, International Immunopharmacology CrossRef
  12. Naltrexone Inhibits IL-6 and TNFα Production in Human Immune Cell Subsets following Stimulation with Ligands for Intracellular Toll-Like Receptors
    Rachel Cant et al, 2017, Frontiers in Immunology CrossRef
  13. Cancer Pain
    Jonathan Silverman et al, 2019, Academic Pain Medicine CrossRef
  14. Low-dose naltrexone as a treatment for chronic fatigue syndrome
    Monica Jane Bolton et al, 2020, BMJ Case Reports CrossRef